Alergia: badanie kliniczne
Efficacy and Safety of Low-dose Sesame Oral Immunotherapy in Pediatric Patients
Badania kliniczne, które rekrutują lub wkrótce zaczną rekrutację w ośrodkach w mieście Warszawa. Najwięcej badań dotyczy: nieswoiste zapalenia jelit, rak płuca, chłoniak, wrzodziejące zapalenie jelita grubego.
1150 badań: 1051 rekrutuje, 99 wkrótce zacznie.
Efficacy and Safety of Low-dose Sesame Oral Immunotherapy in Pediatric Patients
Multimodality Imaging and Functional Lesion Assessment in Intermediate Coronary Stenosis in Chronic Coronary Syndrome
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Angio-based Final Functional Effect of PCI
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C…
An open-label Extension study to evaluate rozanolixizumab in pediatric study participants with generalized myasthenia gravis
A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine…
Adjuvant Tebentafusp in High Risk Ocular Melanoma
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Absolute quantification of myocardial blood flow in human subjects with SYN2 dynamic PET imaging
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
Platform Clinical Study for Conquering Scleroderma
Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder
The STOP-MED CTRCD Trial
An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand…
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL
A Phase III Prospective, Multicenter, Open-label Study to Assess Diagnostic Efficacy of a Novel 18F-labelled Tracer, SYN2, for Positron Emission Tomography in Subjects with…
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small…
Zadzwoń i porozmawiaj z doradcą ds. badań klinicznych. Sprawdzimy w rejestrach, do których badań możesz się kwalifikować.
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 2 października 2026.